R1VT34 Stock Overview Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Revvity, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Revvity Historical stock prices Current Share Price US$24.87 52 Week High US$26.00 52 Week Low US$18.06 Beta 1.03 1 Month Change 4.63% 3 Month Change 0.12% 1 Year Change 32.64% 3 Year Change -37.11% 5 Year Change n/a Change since IPO 67.23%
Recent News & Updates
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Nov 20
Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Nov 06
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Nov 05 Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025
Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 07
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Jul 30 See more updates
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Nov 20
Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Nov 06
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Nov 05 Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025
Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 07
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Jul 30
Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024 Jul 26
Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 10
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Apr 30
Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024 Apr 27
Revvity Unveils A New Era of Automated Tuberculosis Testing Apr 24
Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Apr 05
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 Mar 21
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication Mar 20
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research Mar 15
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions Feb 13
Revvity Showcases Cutting-Edge Solutions at SLAS2024 Feb 02
Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024 Feb 01
Revvity, Inc., Annual General Meeting, Apr 23, 2024 Jan 27 Revvity, Inc. Announces Board Elections, Effective February 1, 2024
Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024 Jan 10
Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023 Jan 09
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Nov 29
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Nov 28
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Oct 31
Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024 Oct 27
Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 10
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure Sep 27
Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries Sep 06
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Aug 02
Revvity Declares Quarterly Dividend, Payable on November 10, 2023 Jul 23
Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 13
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research Jun 30
Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development Jun 13 Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.
PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023 Feb 15
PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023 Jan 27 PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns Nov 15
PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 09
PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023 Oct 27 PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022
PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing Sep 27
Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection Sep 23 PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022 New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.
PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors Jul 23
PerkinElmer, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 15 PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Value-Defensive Index
Perkinelmer Introduces Next Generation, Automated Gas Chromatography Platform Jun 22
PerkinElmer Expands Food Safety Testing Portfolio with AOAC Certified Microbial Count Plates Jun 09
PerkinElmer, Inc. Launches BioQule NGS System to Automate Library Preparation Jun 07
PerkinElmer, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022 May 04
PerkinElmer, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 13
PerkinElmer, Inc. Expands in Vivo Instruments Portfolio with Hands-Free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System Apr 08
PerkinElmer, Inc. Introduces First Ready-To-Use HTRF and AlphaLISA Assay Kits for CHO HCP Impurities Detection and Quantification Apr 05
Perkinelmer, Inc. Launches ChemDraw V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft Powerpoint Reports Mar 04
PerkinElmer, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022 Feb 02
PerkinElmer, Inc. Declares Quarterly Dividend, Payable on May 13, 2022 Jan 28
PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021 Jan 12
PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country Channel Partner for Milk and Dairy Testing Solutions Dec 20
PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance Dec 09
PerkinElmer, Inc. Launches Cloud Based Solution to Enable Remote Lab Management Nov 24
PerkinElmer, Inc. Receives U.S. Food and Drug Administration Emergency Use Authorization for PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 Assay Oct 09
PerkinElmer Expands Automated Mycotoxin Detection Kits Portfolio to Include All Major Mycotoxins Aug 21 PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Growth Index
PerkinElmer, Inc. (NYSE:PKI) completed the acquisition of Nexcelom Bioscience LLC from Ampersand Capital Partners. Jun 26
PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire SIRION Biotech GmbH. Jun 23
PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire Nexcelom Bioscience LLC for $260 million. May 13
PerkinElmer, Inc. Provides Earnings Guidance for Second Quarter and Full Year 2021 May 05
Perkinelmer, Inc. Declares Regular Quarterly Dividend, Payable on August 6, 2021 Apr 30
Perkinelmer, Inc. Provides Revenue Guidance for the First Quarter Ended April 4, 2021 Apr 15
PerkinElmer Launches Industry-First CRM Reagent and Consumable Kit to Streamline Cannabis Pesticide Testing Workflows Mar 19
PerkinElmer, Inc., Annual General Meeting, Apr 27, 2021 Mar 11 PerkinElmer, Inc. Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations
PerkinElmer, Inc. Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening Feb 24
PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process Feb 23
Perkinelmer Launches First Cell Painting Kit Feb 18
PerkinElmer Launches Solus One E. coli O157 Pathogen Detection Assay for Beef & Beef Trim Testing Jan 29 PerkinElmer, Inc.'s SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing
PerkinElmer, Inc. to Report Q4, 2020 Results on Feb 02, 2021 Jan 12
PerkinElmer Launches New HPLC, UHPLC and Next Generation Software Solution Nov 17
PerkinElmer, Inc. Launches Its Newest ChemDraw application, ChemOffice+ Cloud to Simplify, Facilitate and Accelerate Chemistry Communication Workflows Nov 11
EUROIMMUN, a PerkinElmer Company, Launches Quantitative ELISA to Measure SARS-CoV-2 Antibodies Against Viral S1 Protein Nov 10 Shareholder Returns R1VT34 BR Life Sciences BR Market 7D 0% 0% 0% 1Y 32.6% 0% 0%
See full shareholder returns
Return vs Market: R1VT34 exceeded the BR Market which returned -13.9% over the past year.
Price Volatility Is R1VT34's price volatile compared to industry and market? R1VT34 volatility R1VT34 Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in BR Market 0% 10% least volatile stocks in BR Market 0%
Stable Share Price: R1VT34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine R1VT34's volatility change over the past year.
About the Company Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Show more Revvity, Inc. Fundamentals Summary How do Revvity's earnings and revenue compare to its market cap? R1VT34 fundamental statistics Market cap R$87.43b Earnings (TTM ) R$1.65b Revenue (TTM ) R$17.40b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) R1VT34 income statement (TTM ) Revenue US$2.72b Cost of Revenue US$1.21b Gross Profit US$1.51b Other Expenses US$1.25b Earnings US$258.26m
Last Reported Earnings
Sep 29, 2024
Earnings per share (EPS) 2.12 Gross Margin 55.37% Net Profit Margin 9.49% Debt/Equity Ratio 40.2%
How did R1VT34 perform over the long term?
See historical performance and comparison Dividends
0.2% Current Dividend Yield When do you need to buy R1VT34 by to receive an upcoming dividend? Revvity dividend dates Ex Dividend Date Jan 16 2025 Dividend Pay Date Feb 13 2025 Days until Ex dividend 20 days Days until Dividend pay date 48 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 01:21 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/29 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Revvity, Inc. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Ishan Majumdar Baptista Research Luke Sergott Barclays
Show 40 more analysts 
